Kiniksa Pharmaceuticals to Present at Upcoming Investor Conferences
Friday, May 29, 2026 1 min read
Key Takeaway: Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) has announced its participation in upcoming investor conferences, including the Jefferies Global Healthcare Conference and the Goldman Sachs Annual Global Healthcare Conference. Management will conduct fireside chats, allowing for insights into the company’s strategies and offerings. Webcasts of the presentations will be available on the company’s website, ensuring stakeholders have access to key information.
Conference Participation Details
Jefferies Global Healthcare Conference
Date: November 18, 2025
Time: 11:30 a.m. GMT / 6:30 a.m. ET
Location: London
Format: Fireside Chat
How to Access
Investors and the general public can listen to both sessions live at:
Archived versions will be available following the live events for a limited time.
Market Sentiment Analysis
POSITIVE FACTORS
Kiniksa Pharmaceuticals will participate in significant investor conferences.
The company is focused on improving patient lives through novel therapies.
Kiniksa has a portfolio of assets that offers potential differentiation.
Full Press Release Details
LONDON, May 29, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that management will participate in fireside chats at the following investor conferences in June:
2026 Jefferies Global Healthcare Conference on Wednesday, June 3 at 8:45 a.m. Eastern Time
Goldman Sachs 47th Annual Global Healthcare Conference on Tuesday, June 9 at 11:20 a.m. Eastern Time
A live webcast of Kiniksa’s presentations will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the events will also be available on Kiniksa’s website within approximately 48 hours after the event.
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.